KDSTEM Inj.
Phase 1Biologic
KDSTEM Inj. is one of 46 biologic programs targeting Chronic Kidney Disease. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
172 competitors in Chronic Kidney Disease
#DrugCompanyPhaseTrials
1Uloric
TakedaPreclinical
Sovaldi
GileadPreclinical
Glucotrol
PfizerPreclinical
Vemlidy
GileadPreclinical
Lorelco
SanofiPreclinical
Activase
RochePreclinical
Flomax
SanofiPreclinical
Januvia
ZZydus Therapeutics Inc.
Preclinical
Baraclude
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Viagra
VViatris Specialty LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for KDSTEM Inj.. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- EEHL Bio Co., Ltd.